Who are botulinum toxin intramuscular injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): OnabotulinumtoxinA 50 UNT [Botox Cosmetic], Intradetrusor Botox Injections, NT 201, Botox infiltration, NAFT500 (adult), NAFT600 (adult).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/botulinum-toxin-intramuscular-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

botulinum toxin intramuscular injection — Competitive Intelligence Brief

botulinum toxin intramuscular injection (botulinum toxin intramuscular injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuromuscular blocker. Area: Neurology.

phase 3 Neuromuscular blocker SNARE complex Neurology Small molecule Live · refreshed every 30 min

Target snapshot

botulinum toxin intramuscular injection (botulinum toxin intramuscular injection) — Guy's and St Thomas' NHS Foundation Trust. Botulinum toxin works by blocking the release of acetylcholine, a neurotransmitter that transmits nerve impulses, thereby reducing muscle spasms and contractions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
botulinum toxin intramuscular injection TARGET	botulinum toxin intramuscular injection	Guy's and St Thomas' NHS Foundation Trust	phase 3	Neuromuscular blocker	SNARE complex
OnabotulinumtoxinA 50 UNT [Botox Cosmetic]	OnabotulinumtoxinA 50 UNT [Botox Cosmetic]	Amir Moradi MD, MBA	marketed	Botulinum toxin	SNARE complex (synaptosome-associated protein)
Intradetrusor Botox Injections	Intradetrusor Botox Injections	The Methodist Hospital Research Institute	marketed	Neurotoxin; botulinum toxin type A	SNARE complex (synaptosomal-associated protein); acetylcholine release machinery
NT 201	NT 201	Merz Aesthetics GmbH	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery)
Botox infiltration	Botox infiltration	University Rovira i Virgili	marketed	Neurotoxin; botulinum toxin type A	SNARE complex (synaptosome-associated protein); acetylcholine release machinery
NAFT500 (adult)	NAFT500 (adult)	Merz North America, Inc.	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery)
NAFT600 (adult)	NAFT600 (adult)	Merz North America, Inc.	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuromuscular blocker class)

Guy's and St Thomas' NHS Foundation Trust · 1 drug in this class
University Hospital, Rouen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). botulinum toxin intramuscular injection — Competitive Intelligence Brief. https://druglandscape.com/ci/botulinum-toxin-intramuscular-injection. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab